Real‐World Data on the Use of Follitropin Delta in a Dutch IVF Center

Research Question How does follitropin delta administered with an individualized dose based on body weight and AMH perform in daily practice, and is this comparable to results from a randomized phase III clinical trial in terms of ovarian response, pregnancy, and safety? Design This is a descriptive analysis of real‐world data obtained from the Erasmus University Medical Centre (EMC). Patients were treated with the dose of follitropin delta calculated according to the algorithm described in the ESTHER‐1 trial. Outcome data were restricted to the first IVF cycle in patients with a regular ovulatory cycle treated with a GnRH antagonist protocol for whom the intended day of embryo transfer was day 5. Results The ongoing pregnancy rate was 30.8% per started cycle, which is equivalent to the ESTHER‐1 trial. The number of oocytes retrieved (10.3 ± 5.4) was also comparable. All other ovarian response parameters were within the range that was expected on the basis of the results of the ESTHER‐1 trial. Conclusions The use of follitropin delta in a real‐world clinical setting results in ovarian response outcomes comparable in range to those in the follitropin delta arm of the ESTHER‐1 registration trial. No differences were observed in treatment outcomes.